{"nctId":"NCT01181479","briefTitle":"Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System","startDateStruct":{"date":"2010-08"},"conditions":["Contraception"],"count":1504,"armGroups":[{"label":"AG200-15 (cycles 1-13)","type":"EXPERIMENTAL","interventionNames":["Drug: AG200-15 (cycles 1-13)"]},{"label":"Lessina crossover to AG200-15","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lessina crossover to AG200-15"]}],"interventions":[{"name":"AG200-15 (cycles 1-13)","otherNames":["transdermal patch"]},{"name":"Lessina crossover to AG200-15","otherNames":["hormonal oral contraception and transdermal patch"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nHealthy females\n\n* 17(in states where the legal age of consent to receive contraceptives is 17)-40 years\n* Regular, consistent menstrual cycles between 25 and 35 days\n* Sexually active women requesting birth control\n* In good general health, confirmed by medical history, physical (including gynecologic) examination and screening laboratory values\n\nExclusion Criteria:\n\n* Known or suspected pregnancy;\n* Lactating women\n* Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape\n* Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)\n* Use of other contraceptive methods than study medication","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"17 Years","maximumAge":"40 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pregnancy","description":"Pregnancy outcomes was determine by measuring Pearl index. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.41","spread":null},{"groupId":"OG001","value":"6.67","spread":null},{"groupId":"OG002","value":"6.43","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cycle Control","description":"Measuring the breakthrough bleeding (BTB) and/or breakthrough spotting (BTS). Measured as a percent of total number of cycles in each Arm/Group with BTB and/or BTS.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":null},{"groupId":"OG001","value":"21.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Pharmacokinetics of Levonorgestrel (LNG) and Ethinyl Estradiol (EE)","description":"Measurement of plasma concentrations of LNG and EE for cycles 2, 6 and 13.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":null},{"groupId":"OG001","value":"30.5","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.1","spread":null},{"groupId":"OG001","value":"36.7","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"33.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2386","spread":null},{"groupId":"OG001","value":"1201","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2611","spread":null},{"groupId":"OG001","value":"1753","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"1590","spread":null},{"groupId":"OG002","value":"1750","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Self-reported Irritation at Application Site","description":"Evaluation of irritation at application site was determined using the following scores:\n\n0: None\n\n1. Mild\n2. Moderate\n3. Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.35","spread":"0.964"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Patch Adhesion by Investigator Evaluation at Each Visit","description":"Evaluation of patch adhesion was determined using the following scores:\n\n0: \\>= 90% adhered (no lift)\n\n1. \\>= 75% adhered but \\< 90% (some edges showing lift)\n2. \\>= 50% adhered but \\< 75% (half of system lifts off)\n3. \\< 50% (\\> half of system lifts off, but undetached)\n4. patch completely detached","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"0.823"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Self-reported Itching at Patch Application Site","description":"Evaluation of itching at patch application site was determined using the following scores:\n\n0: None\n\n1. Mild\n2. Moderate\n3. Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.48","spread":"0.948"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":1273},"commonTop":["Cervical Dysplasia","Nasopharyngitis","Nausea","Headache","Upper respiratory tract infection"]}}}